Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metformin
Drug ID BADD_D01401
Description Metformin is an antihyperglycemic agent of the _biguanide_ class, used for the management of type II diabetes) [FDA label]. Currently, metformin is the first drug of choice for the management of type II diabetes and is prescribed to at least 120 million people worldwide [A176173]. Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. Metformin is commonly described as an _insulin sensitizer_ leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels [A176173]. Another well-known benefit of this drug is modest weight loss. Metformin is the drug of choice for obese type II diabetes patients [A36559]. Metformin was first approved in Canada in 1972 [A36552], followed by 1995 in the USA [FDA label]. This drug is available in regular and extended-release forms [FDA label].
Indications and Usage For use as an adjunct to diet and exercise in adult patients (18 years and older) with NIDDM. May also be used for the management of metabolic and reproductive abnormalities associated with polycystic ovary syndrome (PCOS). Jentadueto is for the treatment of patients when both linagliptin and metformin is appropriate.
Marketing Status Prescription; Discontinued
ATC Code A10BA02
DrugBank ID DB00331
KEGG ID D04966
MeSH ID D008687
PubChem ID 4091
TTD Drug ID D0D7LA
NDC Product Code 0615-8105; 52493-334; 50742-633; 0378-6001; 50742-634; 0378-6002; 60155-001
Synonyms Metformin | Dimethylbiguanidine | Dimethylguanylguanidine | Glucophage | Metformin Hydrochloride | Hydrochloride, Metformin | Metformin HCl | HCl, Metformin
Chemical Information
Molecular Formula C4H11N5
CAS Registry Number 657-24-9
SMILES CN(C)C(=N)N=C(N)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin resistanceSolute carrier family 2, facilitated glucose transporter member 4P14142Not Available9802324; 1587399; 8391425
Insulin resistanceSolute carrier family 2, facilitated glucose transporter member 1P17809Not Available9802324; 1587399; 8391425
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Altered state of consciousness19.07.01.003; 17.02.04.0010.000378%Not Available
Amenorrhoea21.01.02.001; 05.05.01.002--
Amnesia19.20.01.001; 17.03.02.001--
Amylase increased13.05.01.0090.000469%
Anaemia01.03.02.001--
Anaemia macrocytic14.12.01.002; 01.03.02.0020.000182%Not Available
Anaemia megaloblastic14.12.01.003; 01.03.02.0030.000156%Not Available
Anaemia vitamin B12 deficiency14.12.02.001; 01.03.01.0010.000117%Not Available
Anal atresia07.13.05.001; 03.04.06.0010.000065%Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.004--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Angular cheilitis23.03.03.054; 11.01.04.014; 07.05.07.0130.000117%Not Available
Anhedonia19.15.02.007--Not Available
Anhidrosis23.02.03.0010.000182%Not Available
Anion gap increased13.02.01.0140.001212%Not Available
Anorgasmia19.08.01.0010.000026%
Anosmia22.04.03.006; 17.04.04.0010.000052%
Anuria20.01.03.0020.002215%Not Available
Anxiety19.06.02.002--
Aortic valve stenosis02.07.03.0040.000039%Not Available
Apathy19.04.04.0020.000078%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000208%
Aplastic anaemia01.03.03.0020.000052%Not Available
Appendicitis11.01.07.001; 07.19.01.001--
Arrhythmia02.03.02.001--Not Available
Arteriosclerosis24.04.02.0010.000027%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 42 Pages